InflaRx N.V. (NASDAQ:IFRX) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of InflaRx N.V. (NASDAQ:IFRX) have been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $7.3333.

A number of brokerages have recently commented on IFRX. HC Wainwright boosted their price objective on shares of InflaRx from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Cantor Fitzgerald upped their target price on InflaRx from $4.00 to $6.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Wall Street Zen raised InflaRx from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Zacks Research raised InflaRx from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 27th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a research note on Wednesday, June 24th.

InflaRx Price Performance

NASDAQ IFRX opened at $2.10 on Monday. The firm has a market cap of $309.47 million, a P/E ratio of -3.62 and a beta of 2.48. The stock’s 50-day moving average is $1.93 and its 200-day moving average is $1.61. InflaRx has a one year low of $0.80 and a one year high of $2.95.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.04). Equities analysts anticipate that InflaRx will post -0.31 EPS for the current year.

Hedge Funds Weigh In On InflaRx

A number of institutional investors have recently added to or reduced their stakes in IFRX. Sanctuary Advisors LLC bought a new stake in InflaRx during the second quarter worth $25,000. Cubist Systematic Strategies LLC increased its stake in shares of InflaRx by 33.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after purchasing an additional 7,616 shares during the last quarter. AXQ Capital LP bought a new stake in shares of InflaRx in the 2nd quarter valued at about $41,000. HRT Financial LP acquired a new stake in InflaRx in the 4th quarter valued at about $47,000. Finally, Concurrent Investment Advisors LLC grew its holdings in InflaRx by 56.9% during the fourth quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock worth $53,000 after purchasing an additional 19,200 shares during the period. 42.39% of the stock is currently owned by institutional investors and hedge funds.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.